M
Mark T. Brown
Researcher at Pfizer
Publications - 53
Citations - 5168
Mark T. Brown is an academic researcher from Pfizer. The author has contributed to research in topics: Tanezumab & Placebo. The author has an hindex of 26, co-authored 52 publications receiving 4571 citations.
Papers
More filters
Journal ArticleDOI
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nancy A. Nussmeier,Andrew Whelton,Mark T. Brown,Richard M. Langford,Andreas Hoeft,Joel L. Parlow,Steven W. Boyce,Kenneth M. Verburg +7 more
TL;DR: The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances.
Journal ArticleDOI
Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations
Patrick J. McGrath,Gary A. Walco,Dennis C. Turk,Robert H. Dworkin,Mark T. Brown,Karina W. Davidson,Christopher Eccleston,G. Allen Finley,Kenneth R. Goldschneider,Lynne Haverkos,Sharon Hertz,Gustaf Ljungman,Tonya M. Palermo,Bob A. Rappaport,Thomas Rhodes,Neil L. Schechter,Jane Scott,Navil F. Sethna,Ola Svensson,Jennifer Stinson,Carl L. von Baeyer,Lynn S. Walker,Steven J. Weisman,Richard E. White,Anne Zajicek,Lonnie K. Zeltzer +25 more
TL;DR: Based on systematic review and consensus of experts, core domains and measures for clinical trials to treat pain in children and adolescents were defined to assist in comparison and pooling of data and promote evidence-based treatment.
Journal ArticleDOI
Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee
Nancy E Lane,Thomas J. Schnitzer,C. Birbara,Masoud Mokhtarani,David L. Shelton,Michael D. Smith,Mark T. Brown +6 more
TL;DR: Treatment with tanezumab was associated with a reduction in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee.
Journal ArticleDOI
Efficacy and safety of tanezumab in the treatment of chronic low back pain
Nathaniel P. Katz,David G. Borenstein,C. Birbara,Candace Bramson,Mary Anne Nemeth,Michael D. Smith,Mark T. Brown +6 more
TL;DR: Intravenous tanezumab produces clinically and statistically superior analgesic efficacy compared to placebo and naproxen, with few adverse events in patients with chronic low back pain.